ReviewNanomedicine (London, England)2025
Nanocarrier-enabled delivery of natural antiobesity agents.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sol-gel derived silica-based 58S bioactive glass as a carrier forRSC advances · 2026Article
- Platelet Lysate-Based Biomaterials for Regenerative Tissue Engineering: A Comprehensive Review.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity has become a global epidemic, significantly impacting public health and contributing to the rise of metabolic syndrome, which is closely linked to cardiovascular disease, type 2 diabetes, nonalcoholic fatty liver disease, and certain cancers. Despite the availability of lifestyle interventions, pharmacotherapy, and bariatric surgery, current treatment strategies often face limitations, including poor efficacy, adverse effects, and low patient compliance. Natural compounds such as polyphenols, alkaloids, saponins, and anthraquinones have emerged as promising alternatives because of their multitargeted actions and relatively favorable safety profiles. However, their clinical applications are often hindered by poor solubility, chemical instability, limited bioavailability, and even potential toxicity. Recent advances in nanotechnology-based drug delivery systems, including liposomes, lipid-based carriers, polymeric nanoparticles, mesoporous silica nanoparticles (MSNs), and extracellular vesicles, offer effective solutions to increase the therapeutic efficacy of these natural bioactive compounds. This review provides an overview of obesity and its associated risks, and the therapeutic potential of natural compounds for obesity-related complications, highlights how nanoformulations improve antiobesity effects, and discusses current challenges and future directions for translating these nano-enabled strategies into clinical practice. Relevant literature was collected from databases such as PubMed, Scopus, and Google Scholar, focusing on natural bioactives, obesity, and nanoparticle-assisted drug delivery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.